MIRA Pharmaceuticals (NASDAQ:MIRA) Issues Quarterly Earnings Results

MIRA Pharmaceuticals (NASDAQ:MIRA) issued its quarterly earnings results on Friday. The company reported ($0.15) EPS for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.14, Zacks reports.

MIRA Pharmaceuticals Trading Down 3.6 %

Shares of MIRA stock opened at $1.06 on Friday. The firm has a market capitalization of $17.55 million, a P/E ratio of -1.89 and a beta of 2.31. MIRA Pharmaceuticals has a 1 year low of $0.51 and a 1 year high of $5.01. The firm’s fifty day simple moving average is $1.12 and its 200 day simple moving average is $1.22.

About MIRA Pharmaceuticals

MIRA Pharmaceuticals, Inc operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.